Immunotoxins Targeting B cell Malignancy—Progress and Problems With Immunogenicity
Abstract
:1. Introduction
2. Pseudomonas Exotoxin-Based Moxetumomab
3. Diphtheria Toxin-Based DT2219
4. Deimmunization of Pseudomonas Exotoxin
5. Deimmunization of Diphtheria Toxin
5.1. Chemo-Immunosuppression of the Immune System
5.2. Going Forward
6. Conclusions
Funding
Conflicts of Interest
References
- Manoukian, G.; Hagemeister, F. Denileukin diftitox: A novel immunotoxin. Expert Opin. Biol. Ther. 2009, 9, 1445–1451. [Google Scholar] [CrossRef] [PubMed]
- Wilson, B.A.; Collier, R.J. Diphtheria toxin and Pseudomonas aeruginosa exotoxin A: Active-site structure and enzymic mechanism. Curr. Top Microbiol Immunol. 1992, 175, 27–41. [Google Scholar] [PubMed]
- Yamaizumi, M.; Mekada, E.; Uchida, T.; Okada, Y. One molecule of diphtheria toxin fragment A introduced into a cell can kill the cell. Cell 1978, 15, 245–250. [Google Scholar] [CrossRef]
- Kreitman, R.J.; Pastan, I. Accumulation of a recombinant immunotoxin in a tumor in vivo: Fewer than 1000 molecules per cell are sufficient for complete responses. Cancer Res. 1998, 58, 968–975. [Google Scholar] [PubMed]
- Kreitman, R.J.; Dearden, C.; Zinzani, P.L.; Delgado, J.; Karlin, L.; Robak, T.; Gladstone, D.E.; le Coutre, P.; Dietrich, S.; Gotic, M. Moxetumomab pasudotox in relapsed/refractory hairy cell leukemia. Leukemia 2018, 32, 1768–1777. [Google Scholar] [CrossRef] [PubMed]
- Mazor, R.; Onda, M.; Pastan, I. Immunogenicity of therapeutic recombinant immunotoxins. Immunol. Rev. 2016, 270, 152–164. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Aldoss, I.; Song, J.; Stiller, T.; Nguyen, T.; Palmer, J.; O’Donnell, M.; Stein, A.S.; Marcucci, G.; Forman, S.; Pullarkat, V. Correlates of resistance and relapse during blinatumomab therapy for relapsed/refractory acute lymphoblastic leukemia. Am. J. Hematol. 2017, 2, 858–865. [Google Scholar] [CrossRef]
- Jackson, H.J.; Brentjens, R.J. Overcoming Antigen Escape with CAR T.-cell Therapy. Cancer Discov. 2015, 5, 1238–1240. [Google Scholar] [CrossRef] [PubMed]
- Vallera, D.A.; Todhunter, D.A.; Kuroki, D.W.; Shu, Y.; Sicheneder, A.; Chen, H. A bispecific recombinant immunotoxin, DT2219, targeting human CD19 and CD22 receptors in a mouse xenograft model of B-cell leukemia/lymphoma. Clin. Cancer Res. 2005, 11, 3879–3888. [Google Scholar] [CrossRef] [PubMed]
- Bachanova, V.; Frankel, A.E.; Cao, Q.; Lewis, D.; Grzywacz, B.; Verneris, M.R.; Ustun, C.; Lazaryan, A.; McClune, B.; Warlick, E.D.; et al. Phase I study of a bispecific ligand-directed toxin targeting CD22 and CD19 (DT2219) for refractory B.-cell malignancies. Clin. Cancer Res. 2015, 21, 1267–1272. [Google Scholar] [CrossRef] [PubMed]
- Onda, M.; Nagata, S.; FitzGerald, D.J.; Beers, R.; Fisher, R.J.; Vincent, J.J.; Lee, B.; Nakamura, M.; Hwang, J.; Kreitman, R.J.; et al. Characterization of the B cell epitopes associated with a truncated form of Pseudomonas exotoxin (PE38) used to make immunotoxins for the treatment of cancer patients. J. Immunol. 2006, 177, 8822–8834. [Google Scholar] [CrossRef] [PubMed]
- Onda, M.; Beers, R.; Xiang, L.; Nagata, S.; Wang, Q.C.; Pastan, I. An immunotoxin with greatly reduced immunogenicity by identification and removal of B. cell epitopes. Proc. Natl. Acad. Sci. USA 2008, 105, 11311–11316. [Google Scholar] [CrossRef] [PubMed]
- Mazor, R.; Eberle, J.A.; Hu, X.; Vassall, A.N.; Onda, M.; Beers, R.; Lee, E.C.; Kreitman, R.J.; Lee, B.; Baker, D.; et al. Recombinant immunotoxin for cancer treatment with low immunogenicity by identification and silencing of human T.-cell epitopes. Proc. Natl. Acad. Sci. USA 2014, 111, 8571–8576. [Google Scholar] [CrossRef] [PubMed]
- Schmohl, J.U.; Todhunter, D.; Oh, S.; Vallera, D.A. Mutagenic Deimmunization of Diphtheria Toxin for Use in Biologic Drug Development. Toxins (Basel) 2015, 7, 4067–4082. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Schmohl, J.U.; Todhunter, D.; Taras, E.; Bachanova, V.; Vallera, D.A. Development of a Deimmunized Bispecific Immunotoxin dDT2219 against B.-Cell Malignancies. Toxins (Basel) 2018, 10, 32. [Google Scholar] [CrossRef] [PubMed]
- Hassan, R.; Miller, A.C.; Sharon, E.; Thomas, A.; Reynolds, J.C.; Ling, A.; Kreitman, R.J.; Miettinen, M.M.; Steinberg, S.M.; Fowler, D.H.; et al. Major cancer regressions in mesothelioma after treatment with an anti-mesothelin immunotoxin and immune suppression. Sci. Transl. Med. 2013, 5, 208ra147. [Google Scholar] [CrossRef] [PubMed]
- Kreitman, R.J.; Stetler-Stevenson, M.; Jaffe, E.S.; Conlon, K.C.; Steinberg, S.M.; Wilson, W.; Waldmann, T.A.; Pastan, I. Complete Remissions of Adult T-cell Leukemia with Anti-CD25 Recombinant Immunotoxin LMB-2 and Chemotherapy to Block Immunogenicity. Clin. Cancer Res. 2016, 22, 310–318. [Google Scholar] [CrossRef] [PubMed]
- Wayne, A.S.; Shah, N.N.; Bhojwani, D.; Silverman, L.B.; Whitlock, J.A.; Stetler-Stevenson, M.; Sun, W.; Liang, M.; Yang, J.; Kreitman, R.J.; et al. Phase 1 study of the anti-CD22 immunotoxin moxetumomab pasudotox for childhood acute lymphoblastic leukemia. Blood 2017, 130, 1620–1627. [Google Scholar] [CrossRef] [PubMed]
- Frankel, A.E.; Woo, J.H.; Ahn, C.; Foss, F.M.; Duvic, M.; Neville, P.H.; Neville, D.M. Resimmune, an anti-CD3ε recombinant immunotoxin, induces durable remissions in patients with cutaneous T-cell lymphoma. Haematologica 2015, 100, 794–800. [Google Scholar] [CrossRef] [PubMed]
Drug | IC50 (nM) | Induces NA | Reference |
---|---|---|---|
mutated deimmunized DTEGF13 (dDTEGF13) | 0.03 | − | [12] |
parental DTEGF13 | 0.01 | + | |
Cell line control | >100 | NA | |
mutated deimmunized DT2219 (dDT2219) | 1.0 | − | [13] |
parental DT2219 | 0.3 | + | |
Control anti-CD3 DT | >100 | NA |
© 2018 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
Share and Cite
Vallera, D.A.; Kreitman, R.J. Immunotoxins Targeting B cell Malignancy—Progress and Problems With Immunogenicity. Biomedicines 2019, 7, 1. https://doi.org/10.3390/biomedicines7010001
Vallera DA, Kreitman RJ. Immunotoxins Targeting B cell Malignancy—Progress and Problems With Immunogenicity. Biomedicines. 2019; 7(1):1. https://doi.org/10.3390/biomedicines7010001
Chicago/Turabian StyleVallera, Daniel A., and Robert J. Kreitman. 2019. "Immunotoxins Targeting B cell Malignancy—Progress and Problems With Immunogenicity" Biomedicines 7, no. 1: 1. https://doi.org/10.3390/biomedicines7010001